Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: Efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer
Phase 2
- Conditions
- Breast cancer patients who have received chemotherapy either before or after surgery are the study subjects
- Registration Number
- JPRN-UMIN000000610
- Lead Sponsor
- Japan Breast Cancer Research Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 240
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Pregnant or breast feeding. (2) Bilateral or inflammatory breast cancer. (3) Multiple cancers. (4) Life-threatening metastases. (5) History of serious hypersensitivity. (6) Judged ineligible for the study by the study doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence-free rate
- Secondary Outcome Measures
Name Time Method - Survival rate. - Drug adverse events. - Bone metabolism markers (BAP, NTx). - BMD (DXA method): Lumbar vertebrae, femoral neck. - Laboratory values of lipid metabolism (TC, LDL, HDL, Lp(a), TG). - Compliance.